The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

This was the stock's third consecutive day of losses.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In the latest close session, Pfizer (PFE) was up +1.51% at $25.62. The stock's performance was ahead of the S&P 500's daily loss of 0.07%. Elsewhere, the Dow saw a downswing of 0.37%, while the ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Over 50 listed companies including Sun Pharma, Mphasis, Pfizer, Veedol, Dr Reddy's Laboratories have announced final ...